MDMA Therapy Is Rejected by FDA Panel
Scientific advisers vote overwhelmingly that the risks of MDMA treatment for post-traumatic stress disorder outweigh the benefits
![MDMA Therapy Is Rejected by FDA Panel](https://static.scientificamerican.com/dam/m/498cc61b67ce3b8f/original/GettyImages-566464211_WEB.jpg?w=1200)
Scientific advisers vote overwhelmingly that the risks of MDMA treatment for post-traumatic stress disorder outweigh the benefits
What's Your Reaction?
![like](https://news.sciencex.in/assets/img/reactions/like.png)
![dislike](https://news.sciencex.in/assets/img/reactions/dislike.png)
![love](https://news.sciencex.in/assets/img/reactions/love.png)
![funny](https://news.sciencex.in/assets/img/reactions/funny.png)
![angry](https://news.sciencex.in/assets/img/reactions/angry.png)
![sad](https://news.sciencex.in/assets/img/reactions/sad.png)
![wow](https://news.sciencex.in/assets/img/reactions/wow.png)